Michael A. Metzger has been appointed president and chief operating officer at Regado Biosciences, and joins the executive management team. Mr. Metzger will oversee corporate and business development strategy and planning, as well as other key business functions of the company.
Mr. Metzger has 20 years of experience in the life sciences sector. He previously served as executive vice president and chief operating officer at Mersana Therapeutics, where he drove the establishment and management of key business alliances and was one of the architects of the strategic direction, financing and growth of the business. Prior to Mersana, Mr. Metzger held senior positions in business development and led mergers and acquisitions at Forest Laboratories. Mr. Metzger also served as vice president of corporate development at Onconova Therapeutics, and managing director at MESA Partners, a venture capital firm.
"We are delighted to have Michael joining Regado. His background in corporate and business development along with his operational experience will enhance our already high performing team. We look forward to his contributions and to collectively bringing REG1 and the entire Regado pipeline through successful development. It is my expectation that Michael will quickly become an asset to Regado and will help us establish the new standard of care in anticoagulant therapy, starting with REG1 in PCI," said David J. Mazzo, Ph.D., chief executive officer.